Published in

Cold Spring Harbor Laboratory Press, Genes & Development, 14(21), p. 1714-1719, 2007

DOI: 10.1101/gad.1549407

Links

Tools

Export citation

Search in Google Scholar

Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis

Journal article published in 2007 by Brooke Ancrile, Kian-Huat Lim ORCID, Christopher M. Counter
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Ras is mutated to remain in the active oncogenic state in many cancers. As Ras has proven difficult to target therapeutically, we searched for secreted, druggable proteins induced by Ras that are required for tumorigenesis. We found that Ras induces the secretion of cytokine IL6 in different cell types, and that knockdown of IL6, genetic ablation of the IL6 gene, or treatment with a neutralizing IL6 antibody retard Ras-driven tumorigenesis. IL6 appears to act in a paracrine fashion to promote angiogenesis and tumor growth. Inhibiting IL6 may therefore have therapeutic utility for treatment of cancers characterized by oncogenic Ras mutations.